Molecularly Adapted Antitumor Therapy for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Two-Year Follow-Up Results
Marat Mingalimov, Elena Baryakh, Andrey Misyurin, Laura Kesaeva, Hasmik Mkrtchyan, Elena Misyurina, Mariia Orlova, Tatiana Tolstykh, Ekaterina Zotina, Liliia Shimanovskaia, Tatiana Chudnova, Diana Ivanova, Olga Kochneva, Kseniya Tsurkina, Dmitry Lebedev, Georgii Tyshkevich, Natalia Bekreneva, Viktor · 2026
Read Molecularly Adapted Antitumor Therapy for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Two-Year Follow-Up Results by Marat Mingalimov, Elena Baryakh, Andrey Misyurin, Laura Kesaeva, Hasmik Mkrtchyan, Elena Misyurina, Mariia Orlova, Tatiana Tolstykh, Ekaterina Zotina, Liliia Shimanovskaia, Tatiana Chudnova, Diana Ivanova, Olga Kochneva, Kseniya Tsurkina, Dmitry Lebedev, Georgii Tyshkevich, Natalia Bekreneva, Viktor (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13116961.txt.
Description
Background/Objectives: Diffuse large B-cell lymphoma (DLBCL) is molecularly heterogeneous, and approximately 30-50% of patients fail to achieve cure with standard R-CHOP. Genotype-directed first-line therapy may improve outcomes by targeting subtype-specific oncogenic pathways. This study evaluated the feasibility, efficacy, and safety of a molecularly adapted R-CHOP-X strategy with two-year follow-up.
Catalog record
| CREATOR | Marat Mingalimov, Elena Baryakh, Andrey Misyurin, Laura Kesaeva, Hasmik Mkrtchyan, Elena Misyurina, Mariia Orlova, Tatiana Tolstykh, Ekaterina Zotina, Liliia Shimanovskaia, Tatiana Chudnova, Diana Ivanova, Olga Kochneva, Kseniya Tsurkina, Dmitry Lebedev, Georgii Tyshkevich, Natalia Bekreneva, Viktor |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |